Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

XORTX Therapeutics Inc. (C:XRX)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for XRX within the last 6 months
See all filings within the past 6 months

Company News

Jun 23, 2020 07:00 ET
XORTX Announces Mr. Anthony J. Giovinazzo to Join as Special Advisor to the Board of Directors
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that Mr. Anthony J. Giovinazzo will...
Read full article
May 19, 2020 09:38 ET
XORTX Provides Program Update Regarding XRx-008 for ADPKD and XRx-101 for Coronavirus / COVID-19 Programs
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF) (FRANKFURT: ANU1), a biopharmaceutical company focused on developing innovative therapies to treat kidney disease, is pleased to provide the following update on its...
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 30, 202014,5008,440
Jun 15, 20206,0603,158
May 31, 20202,902-4,355
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

XORTX Therapeutics Inc, formerly APAC Resources Inc, is Canada-based biopharmaceutical Company. The Company focuses on developing therapies to treat progressive kidney disease. XORTX Therapeutics Inc has programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. Its development programs focus on potential treatments for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Diabetic Nephropathy (DN). Its pipeline products: Autosomal Dominant Polycystic Kidney Disease is in Phase II clinical trial, Diabetic Nephropathy is in Phase I clinical trial, and NASH is in the pre-clinical stage.

See business summary



Search (past week) for $XRX.CA

  • No tweets found